Latest Breaking News On - Iterum therapeutics plc - Page 4 : comparemela.com
Zacks Investment Research Downgrades Iterum Therapeutics (NASDAQ:ITRM) to Hold
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Will These Penny Stocks Grow As The Biotech Sector Pushes Up?
With penny stocks, high volatility can often be used as an asset. While buying penny stocks is not for everyone, the potential with stocks under $5 can be high. On the other hand, some investors will shy away from penny stocks because of the high risk associated. And while high risk can be scary, if you do the research, making money with penny stocks can be easy.Â
Ask any trader, and theyâll tell you that there is no secret trick to investing. However, getting a proper education in trading will be your most valuable asset. Often, new investors will look for the most trending penny stocks, and use this to create a watchlist. But, there are many other factors to consider. With biotech penny stocks, there are a few additional aspects to keep in mind.Â
Neos Therapeutics Inc. (NASDAQ: NEOS)Penny Stocks To Watch #1: PharmaDrug Inc.
When you think about biotech, the first thing that might come to mind are labs designed for developing cancer treatments or vaccines. But have you thought about how this market niche has evolved over the last few years? With the inclusion of things like ânatural medicines,â weâve seen everything from cannabis to psychedelics being explored by companies. In this case, PharmaDrug is concentrating on both.
Specific to the pharmaceutical market potential of alternative medicines, the studies focusing on psychedelics primarily target mental health concerns. Weâre talking about a market (central nervous system therapeutics) worth nearly $205 billion by 2028. While the âcannabis playâ for PharmaDrug focuses on the German market, its advancement in R&D for psychedelics is getting much more attention. Furthermore, the company isnât âjust another mushroom stock.â Itâ�
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
February 09, 2021 23:58 ET | Source: Iterum Therapeutics plc Iterum Therapeutics plc Dublin 2, IRELAND
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 17,500,000 of its ordinary shares at a purchase price of $2.00 per ordinary share in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to close on or about February 12, 2021, subject to the s
vimarsana © 2020. All Rights Reserved.